Baxter International acquired Recothrom and Preveleak from Mallinckrodt, expanding its surgical portfolio of hemostats and sealants, according to Zenopa.
Here are four details to note.
1. Baxter paid $153 million upfront, but future contingent payments could be required.
2. Recothrom is the only topical hemostat from recombinant DNA to be approved in the U.S. and Canada.
3. Preveleak is a surgical sealant used in vascular reconstruction. It is approved for use in Europe and the U.S.
4. Baxter's Advanced Surgery Division President Wil Boren said the acquisition offers additional options for addressing intraoperative bleeding.
"Our top priority right now is working with customers and distributors to ensure a smooth transition," Mr. Boren said.